XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, has elected to voluntarily delist its common shares from the TSX Venture Exchange. The company aims to eliminate duplicate exchange fees, reduce legal and accounting expenses, optimize financing initiatives, and simplify regulatory compliance by maintaining a single listing on t…